1.Sporadic Porphyria Cutanea Tarda in a Patient with Multiple Sclerosis Treated with Interferon Beta 1-a Therapy: A Case Report.
Pietro CARRIERI ; Maria PETRACCA ; Silvana MONTELLA ; Giovanni CERULLO ; Ilaria CERILLO ; Gianfranco CIMMINO
Journal of Clinical Neurology 2013;9(3):196-197
No abstract available.
Humans
;
Interferon-beta
;
Interferons
;
Multiple Sclerosis
;
Porphyria Cutanea Tarda
;
Porphyrias
2.Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis
Antonio CAROTENUTO ; Teresa COSTABILE ; Marcello MOCCIA ; Fabrizia FALCO ; Maria PETRACCA ; Barbara SATELLITI ; Cinzia Valeria RUSSO ; Francesco SACCÀ ; Roberta LANZILLO ; Vincenzo BRESCIA MORRA
International Neurourology Journal 2021;25(4):310-318
Purpose:
The aim of this study was to evaluate the prevalence of bowel/bladder dysfunction in multiple sclerosis (MS) and its associations with cognitive impairment.
Methods:
We prospectively enrolled 150 MS patients. Patients were administered the Symbol Digit Modality Test (SDMT), the Neurogenic Bowel Dysfunction Score (NBDS), and the Actionable Bladder Symptom Screening Tool (ABSST). The associations between bowel/bladder dysfunction and cognitive function were assessed through hierarchical regression models using the SDMT and clinicodemographic features as independent variables and NBDS and ABSST scores as dependent variables.
Results:
The prevalence of bowel/bladder deficits was 44.7%, with 26 patients (17.3%) suffering from bowel deficits and 60 patients (40%) from bladder deficits. The total NBDS and ABSST scores were correlated with the SDMT (β=-0.10, P<0.001 and β=-0.03, P=0.04, respectively) after correction for demographic features and physical disability.
Conclusions
Bowel/bladder disorders are common in MS and are associated with both physical and cognitive disability burdens. As SDMT is embedded into routine clinical assessments, a lower score may warrant investigating bowel/bladder dysfunction due to the strong interplay of these factors.